Ma, Y.; Field, N.R.; Xie, T.; Briscas, S.; Kokinogoulis, E.G.; Skipper, T.S.; Alghalayini, A.; Sarker, F.A.; Tran, N.; Bowden, N.A.;
et al. Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant Subtypes. Cancers 2024, 16, 3068.
https://doi.org/10.3390/cancers16173068
AMA Style
Ma Y, Field NR, Xie T, Briscas S, Kokinogoulis EG, Skipper TS, Alghalayini A, Sarker FA, Tran N, Bowden NA,
et al. Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant Subtypes. Cancers. 2024; 16(17):3068.
https://doi.org/10.3390/cancers16173068
Chicago/Turabian Style
Ma, Yue, Natisha R. Field, Tao Xie, Sarina Briscas, Emily G. Kokinogoulis, Tali S. Skipper, Amani Alghalayini, Farhana A. Sarker, Nham Tran, Nikola A. Bowden,
and et al. 2024. "Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant Subtypes" Cancers 16, no. 17: 3068.
https://doi.org/10.3390/cancers16173068
APA Style
Ma, Y., Field, N. R., Xie, T., Briscas, S., Kokinogoulis, E. G., Skipper, T. S., Alghalayini, A., Sarker, F. A., Tran, N., Bowden, N. A., Dickson, K. -A., & Marsh, D. J.
(2024). Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant Subtypes. Cancers, 16(17), 3068.
https://doi.org/10.3390/cancers16173068